Previous investigations of RA susceptibility markers in determining the response to anti-TNF drugs have found that neither the HLA–DRB1 shared epitope nor the PTPN22 locus is correlated with the response to biologics treatment (23). This evidence concerns the gene TNF and rheumatoid arthritis.